Market Cap : 2.18 B | Enterprise Value : 23.4 B | PE Ratio : 51.50 | PB Ratio : |
---|
NYSE:BHC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NYSE:BHC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Bausch Health's Total Stockholders Equity for the quarter that ended in Jun. 2022 was $-693 Mil. Bausch Health's Total Assets for the quarter that ended in Jun. 2022 was $28,171 Mil. Therefore, Bausch Health's Equity to Asset Ratio for the quarter that ended in Jun. 2022 was -0.03.
The historical rank and industry rank for Bausch Health's Equity-to-Asset or its related term are showing as below:
During the past 13 years, the highest Equity to Asset Ratio of Bausch Health was 0.85. The lowest was -0.03. And the median was 0.34.
BHC's Equity-to-Asset is ranked worse thanThe historical data trend for Bausch Health's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bausch Health's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Bausch Health's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Bausch Health's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Bausch Health's Equity to Asset Ratio for the fiscal year that ended in Dec. 2021 is calculated as
Equity to Asset (A: Dec. 2021 ) | = | Total Stockholders Equity | / | Total Assets |
= | -106 | / | 29202 | |
= | -0.00 |
Bausch Health's Equity to Asset Ratio for the quarter that ended in Jun. 2022 is calculated as
Equity to Asset (Q: Jun. 2022 ) | = | Total Stockholders Equity | / | Total Assets |
= | -693 | / | 28171 | |
= | -0.02 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Thank you for viewing the detailed overview of Bausch Health's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Carson Seana | officer: EVP, General Counsel | 400 SOMERSET CORPORATE BLVD BRIDGEWATER NJ 08807 |
Vadaketh Tom George | officer: EVP, Chief Financial Officer | 1727 JOCKEYS WAY YARDLEY PA 19067 |
Mulligan Richard | director | C/O ICAHN CAPITAL LP 767 FIFTH AVENUE, SUITE 4700 NEW YORK NY 10153 |
Munsch Frederick | officer: SVP, Controller and CAO | 400 SOMERSET CORPORATE BLVD. BRIDGEWATER NJ 08807 |
Gordon Joseph F | officer: Pres&Co-Head Bausch&Lomb/Int'l | 400 SOMERSET CORPORATE BLVD. BRIDGEWATER NJ 08807 |
Ackermann Christina | officer: EVP AND GENERAL COUNSEL | C/O BLCO 400 SOMERSET CORPORATE BLVD. BRIDGEWATER NJ 08807 |
Spurr Robert | director, officer: U.S. President-Pharma Business | C/O BAUSCH HEALTH COMPANIES INC. 400 SOMERSET CORPORATE BLVD. BRIDGEWATER NJ 08807 |
Eldessouky Sam | officer: EVP & Chief Financial Officer | C/O BAUSCH HEALTH COMPANIES INC. 400 SOMERSET CORPORATE BLVD. BRIDGEWATER NJ 08807 |
Miller Steven D | director | 16690 COLLINS AVENUE PH SUNNY ISLE BEACH FL 33160 |
Icahn Brett | director | C/O ICAHN ENTERPRISES L.P. 16690 COLLINS AVE., PH SUNNY ISLES FL 33160 |
Paulson John | director | 1133 AVENUE OF THE AMERICAS 33RD FLOOR NEW YORK NY 10036 |
Valueact Holdings Ii, L.p. | director, other: See Remarks | ONE LETTERMAN DRIVE BUILDING D, FOURTH FLOOR SAN FRANCISCO CA 94129 |
Von Eschenbach Andrew C. | director | BAUSCH HEALTH COMPANIES INC. 400 SOMERSET CORPORATE BLVD. BRIDGEWATER NJ 08807 |
Mckenna Mark C. | officer: President, Salix | 400 SOMERSET CORPORATE BOULEVARD BRIDGEWATER NJ 08807 |
Humphries William D. | officer: EVP, COMPANY GROUP CHAIRMAN | C/O STRATA SKIN SCIENCES, INC. 5 WALNUT GROVE DRIVE SUITE 140 HORSHAM PA 19044 |
Other Sources
By Zacks 2022-01-26
By Zacks 2022-01-24
By tipranks.com 2022-02-23
By Zacks 2022-02-08
By Zacks 2022-02-23
By Zacks 2022-01-31
By Zacks 2022-01-12
By Zacks 2022-03-22
By Zacks 2022-03-25
By Zacks 2022-03-30
By Zacks 2022-02-24
By Zacks 2022-03-10